Through a systematic and critical evaluation of our capabilities and an analysis of unmet medical needs, we prioritize our research and development efforts and focus on candidates that we believe represent breakthrough science that will make a difference for patients and payers.
Our current pipeline and list of marketed products are aligned with major global burdens of disease, based on the Global Burden of Disease 2010 (GBD2010) study.
Our company addresses 88% of the top 20 global burdens of illness.
Using the GBD2010 Visualization tools developed by the Institute for Health Metrics and Evaluation (IHME), the diseases that we address rank high on the list of worldwide causes of death. Our research into vaccines and infectious diseases addresses major burdens of disease that are prevalent in all countries, and our preventative treatments could have the greatest impact in the developing world, where healthcare infrastructure is weak or nonexistent. Considering our pipeline and the list of products we currently market, we estimate that our company addresses 88 percent of the top 20 global burdens of disease as defined by the IHME, excluding road injury, self-harm and preterm birth complications.